{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:19:26Z","timestamp":1794359966989,"version":"4.9.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with psychosis frequently use a variety of psychotropic medicines, many of which have anticholinergic effects that can impair cognition. Therefore, this study aimed to evaluate whether there is an association between medications used for neuropsychological disorders\/symptoms and cognition in patients with schizophrenia, focusing on their anticholinergic load and antipsychotic doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>A cross-sectional study between July 2019 and Mars 2020 at the Psychiatric Hospital of the Cross-Lebanon enrolled 120 inpatients diagnosed with schizophrenia. The total anticholinergic burden was calculated based on the Anticholinergic Drug Scale (ADS), and the chlorpromazine equivalent dose was calculated using the Andreasen method to assess the relative antipsychotic dose. Also, the objective cognition was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS) tool.<\/jats:p>\n                    <jats:p>Study results.<\/jats:p>\n                    <jats:p>\n                      A significantly higher BACS total score (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009-0.33,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), higher verbal memory (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009-0.26,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), higher working memory (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009-0.20,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03), higher motor speed (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009-0.36,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and higher attention and speed of information processing (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009-0.27,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) were significantly associated with lower chlorpromazine equivalent dose. Higher ADS (Standardized Beta (SB)\u2009=\u2009-.22;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.028), higher chlorpromazine equivalent dose (SB\u2009=\u2009-.30;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.001), and taking mood stabilizer medications (SB\u2009=\u2009-.24;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.004) were significantly associated with lower cognition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms that the cognitive functions of chronic patients with schizophrenia may be affected by medications and their anticholinergic burden. More studies are needed to explain the role of cholinergic neurotransmission and general neurochemical mechanisms in the cognitive impairment of patients with schizophrenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-023-04552-y","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T02:04:31Z","timestamp":1674525871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia"],"prefix":"10.1186","volume":"23","author":[{"given":"Chadia","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Sacre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"issue":"3","key":"4552_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","volume":"12","author":"RW Heinrichs","year":"1998","unstructured":"Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426.","journal-title":"Neuropsychology"},{"issue":"6","key":"4552_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.biopsych.2005.01.003","volume":"57","author":"RS Keefe","year":"2005","unstructured":"Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiat. 2005;57(6):688\u201391.","journal-title":"Biol Psychiat"},{"issue":"4","key":"4552_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/schbul\/sbt085","volume":"40","author":"E Bora","year":"2014","unstructured":"Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull. 2014;40(4):744\u201355.","journal-title":"Schizophr Bull"},{"issue":"1","key":"4552_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/070674371405900104","volume":"59","author":"TK Rajji","year":"2014","unstructured":"Rajji TK, Miranda D, Mulsant BH. Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. The Canadian Journal of Psychiatry. 2014;59(1):13\u20137.","journal-title":"The Canadian Journal of Psychiatry"},{"issue":"9","key":"4552_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.biopsych.2008.04.005","volume":"64","author":"D Dickinson","year":"2008","unstructured":"Dickinson D, Ragland JD, Gold JM, Gur RC. General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiat. 2008;64(9):823\u20137.","journal-title":"Biol Psychiat"},{"issue":"1","key":"4552_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","volume":"72","author":"KH Nuechterlein","year":"2004","unstructured":"Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72(1):29\u201339.","journal-title":"Schizophr Res"},{"key":"4552_CR7","first-page":"100199","volume":"25","author":"C Haddad","year":"2021","unstructured":"Haddad C, Salameh P, Sacre H, Cl\u00e9ment J-P, Calvet B. General description of cognitive deficits in schizophrenia and assessment tools in Lebanon: A scoping review. Schizophrenia Research: Cognition. 2021;25:100199.","journal-title":"Schizophrenia Research: Cognition"},{"issue":"3","key":"4552_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1176\/ajp.153.3.321","volume":"153","author":"MF Green","year":"1996","unstructured":"Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? The Am J Psychiatry. 1996;153(3):321\u201330.","journal-title":"The Am J Psychiatry"},{"issue":"1","key":"4552_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","volume":"26","author":"MF Green","year":"2000","unstructured":"Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u201cright stuff\u201d? Schizophr Bull. 2000;26(1):119\u201336.","journal-title":"Schizophr Bull"},{"issue":"5\u20136","key":"4552_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.eurpsy.2005.02.006","volume":"20","author":"A Hofer","year":"2005","unstructured":"Hofer A, Baumgartner S, Bodner T, et al. Patient outcomes in schizophrenia II: the impact of cognition. Eur Psychiatry. 2005;20(5\u20136):395\u2013402.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"4552_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","volume":"70","author":"G D\u00e9sam\u00e9ricq","year":"2014","unstructured":"D\u00e9sam\u00e9ricq G, Schurhoff F, Meary A, et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2014;70(2):127\u201334.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"4552_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1017\/S146114570500516X","volume":"8","author":"ND Woodward","year":"2005","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8(3):457\u201372.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"4552_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","volume":"55","author":"AL Mishara","year":"2004","unstructured":"Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiat. 2004;55(10):1013\u201322.","journal-title":"Biol Psychiat"},{"key":"4552_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fpsyt.2018.00622","volume":"9","author":"NE MacKenzie","year":"2018","unstructured":"MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psych. 2018;9:622.","journal-title":"Front Psych"},{"issue":"6","key":"4552_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","volume":"64","author":"RS Keefe","year":"2007","unstructured":"Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633\u201347.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20133","key":"4552_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","volume":"89","author":"ND Woodward","year":"2007","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007;89(1\u20133):211\u201324.","journal-title":"Schizophr Res"},{"issue":"7","key":"4552_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/0269881108100777","volume":"24","author":"D Elie","year":"2010","unstructured":"Elie D, Poirier M, Chianetta J, Durand M, Gr\u00e9goire C, Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 2010;24(7):1037\u201344.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"4552_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/NMD.0b013e31824cb359","volume":"200","author":"M Torniainen","year":"2012","unstructured":"Torniainen M, Suvisaari J, Partonen T, et al. Cognitive impairments in schizophrenia and schizoaffective disorder: relationship with clinical characteristics. J Nerv Ment Dis. 2012;200(4):316\u201322.","journal-title":"J Nerv Ment Dis"},{"issue":"5","key":"4552_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/schbul\/sbt090","volume":"39","author":"H Takeuchi","year":"2013","unstructured":"Takeuchi H, Suzuki T, Remington G, et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull. 2013;39(5):993\u20138.","journal-title":"Schizophr Bull"},{"issue":"9","key":"4552_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jamapsychiatry.2015.0891","volume":"72","author":"A Graff-Guerrero","year":"2015","unstructured":"Graff-Guerrero A, Rajji TK, Mulsant BH, et al. Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2\/3 receptor occupancy study. JAMA Psychiat. 2015;72(9):927\u201334.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"4552_CR21","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/schbul\/sbq057","volume":"37","author":"F Irani","year":"2011","unstructured":"Irani F, Kalkstein S, Moberg EA, Moberg PJ. Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull. 2011;37(6):1318\u201326.","journal-title":"Schizophr Bull"},{"key":"4552_CR22","first-page":"225","volume":"4","author":"N Campbell","year":"2009","unstructured":"Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225.","journal-title":"Clin Interv Aging"},{"key":"4552_CR23","doi-asserted-by":"crossref","unstructured":"Georgiou R, Lamnisos D, Giannakou K. Anticholinergic burden and cognitive performance in patients with schizophrenia: a systematic literature review. Frontiers in psychiatry. 2021;12:779607.","DOI":"10.3389\/fpsyt.2021.779607"},{"issue":"3","key":"4552_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3371\/CSRP.5.3.2","volume":"5","author":"M Chakos","year":"2011","unstructured":"Chakos M, Patel J, Rosenheck R, et al. Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study. Clin Schizophr Relat Psychoses. 2011;5(3):124\u201334.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"4","key":"4552_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.therap.2016.12.010","volume":"72","author":"J Briet","year":"2017","unstructured":"Briet J, Javelot H, Heitzmann E, et al. The anticholinergic impregnation scale: Towards the elaboration of a scale adapted to prescriptions in French psychiatric settings. Therapies. 2017;72(4):427\u201337.","journal-title":"Therapies"},{"issue":"1","key":"4552_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/pcn.12088","volume":"68","author":"S Ogino","year":"2014","unstructured":"Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014;68(1):37\u201349.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"4552_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/157340009788971137","volume":"5","author":"E Biringer","year":"2009","unstructured":"Biringer E, Rongve A, Lund A. A review of modern antidepressants\u2019 effects on neurocognitive function. Current Psychiatry Reviews. 2009;5(3):164\u201374.","journal-title":"Current Psychiatry Reviews"},{"issue":"12","key":"4552_CR28","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0091270006292126","volume":"46","author":"RM Carnahan","year":"2006","unstructured":"Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481\u20136.","journal-title":"J Clin Pharmacol"},{"key":"4552_CR29","unstructured":"Albert M. Anticholinergic discontinuation for antipsychotic-induced extra-pyramidal symptoms. 2017."},{"issue":"7539","key":"4552_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","volume":"332","author":"ML Ancelin","year":"2006","unstructured":"Ancelin ML, Artero S, Portet F, Dupuy A-M, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455\u20139.","journal-title":"BMJ"},{"issue":"6","key":"4552_CR31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","volume":"73","author":"SL Risacher","year":"2016","unstructured":"Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721\u201332.","journal-title":"JAMA Neurol"},{"issue":"2","key":"4552_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","volume":"81","author":"U Ehrt","year":"2010","unstructured":"Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson\u2019s disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81(2):160\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4552_CR33","doi-asserted-by":"crossref","unstructured":"Joshi YB, Thomas ML, Braff DL, et al. Anticholinergic Medication Burden\u2013Associated Cognitive Impairment in Schizophrenia. American Journal of Psychiatry. 2021;178(9):838-47.","DOI":"10.1176\/appi.ajp.2020.20081212"},{"issue":"6","key":"4552_CR34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/JCP.0000000000000790","volume":"37","author":"M San Ang","year":"2017","unstructured":"San Ang M, Rashid NAA, Lam M, et al. The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J Clin Psychopharmacol. 2017;37(6):651.","journal-title":"J Clin Psychopharmacol"},{"key":"4552_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.schres.2017.03.034","volume":"190","author":"S Eum","year":"2017","unstructured":"Eum S, Hill SK, Rubin LH, et al. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res. 2017;190:129\u201335.","journal-title":"Schizophr Res"},{"issue":"9","key":"4552_CR36","doi-asserted-by":"publisher","first-page":"e1284","DOI":"10.4088\/JCP.17m11523","volume":"78","author":"C Tsoutsoulas","year":"2017","unstructured":"Tsoutsoulas C, Mulsant BH, Kumar S, et al. Anticholinergic burden and cognition in older patients with schizophrenia. The J Clin Psychiatry. 2017;78(9):e1284\u201390.","journal-title":"The J Clin Psychiatry"},{"issue":"1","key":"4552_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-021-03228-9","volume":"21","author":"C Haddad","year":"2021","unstructured":"Haddad C, Salameh P, Hallit S, et al. Cross-cultural adaptation and validation of the Arabic version of the BACS scale (the brief assessment of cognition in schizophrenia) among chronic schizophrenic inpatients. BMC Psychiatry. 2021;21(1):1\u201312.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"4552_CR38","first-page":"14","volume":"36","author":"RM Carnahan","year":"2002","unstructured":"Carnahan RM, Lund BC, Perry PJ, Culp KR, Pollock BG. The relationship of an anticholinergic rating scale with serum anticholinergic activity in elderly nursing home residents. Psychopharmacol Bull. 2002;36(4):14\u20139.","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"4552_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","volume":"67","author":"NC Andreasen","year":"2010","unstructured":"Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho B-C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiat. 2010;67(3):255\u201362.","journal-title":"Biol Psychiat"},{"key":"4552_CR40","unstructured":"ClinCalc. Equivalent Benzodiazepine Calculator. Available at: https:\/\/clincalc.com\/Benzodiazepine\/. [Last Accessed 21 December, 2022]. 2022."},{"issue":"2\u20133","key":"4552_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","volume":"68","author":"RS Keefe","year":"2004","unstructured":"Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2\u20133):283\u201397.","journal-title":"Schizophr Res"},{"key":"4552_CR42","unstructured":"Hallit S, Obeid S, Haddad C, Kazour F, Kazour G. Validation of the Arabic Version of the PANSS scale among Lebanese schizophrenic patients. Journal of Psychopathology. 2017."},{"issue":"2","key":"4552_CR43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261.","journal-title":"Schizophr Bull"},{"issue":"9","key":"4552_CR44","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","volume":"166","author":"S Vinogradov","year":"2009","unstructured":"Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166(9):1055\u201362.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"4552_CR45","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","volume":"161","author":"MJ Minzenberg","year":"2004","unstructured":"Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161(1):116\u201324.","journal-title":"Am J Psychiatry"},{"key":"4552_CR46","doi-asserted-by":"publisher","first-page":"8213165","DOI":"10.1155\/2016\/8213165","volume":"2016","author":"M Rehse","year":"2016","unstructured":"Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D. Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. Schizophr Res Treatment. 2016;2016:8213165.","journal-title":"Schizophr Res Treatment"},{"issue":"5","key":"4552_CR47","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41386-019-0573-7","volume":"45","author":"H Tani","year":"2020","unstructured":"Tani H, Takasu S, Uchida H, Suzuki T, Mimura M, Takeuchi H. Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. Neuropsychopharmacology. 2020;45(5):887\u2013901.","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"4552_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.schres.2006.05.004","volume":"86","author":"H Hori","year":"2006","unstructured":"Hori H, Noguchi H, Hashimoto R, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res. 2006;86(1\u20133):138\u201346.","journal-title":"Schizophr Res"},{"issue":"1","key":"4552_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00004850-200201000-00007","volume":"17","author":"S Moritz","year":"2002","unstructured":"Moritz S, WoodwardKrausz TM, Naber D, Group PS. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. Int Clin Psychopharmacol. 2002;17(1):41\u20134.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"4552_CR50","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/13651501.2011.631018","volume":"16","author":"H Hori","year":"2012","unstructured":"Hori H, Yoshimura R, Katsuki A, et al. Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients. Int J Psychiatry Clin Pract. 2012;16(2):138\u201342.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"4","key":"4552_CR51","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0269881112466183","volume":"27","author":"T Veselinovi\u0107","year":"2013","unstructured":"Veselinovi\u0107 T, Schorn H, Vernaleken IB, et al. Effects of antipsychotic treatment on cognition in healthy subjects. J Psychopharmacol. 2013;27(4):374\u201385.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"4552_CR52","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.pnpbp.2010.07.029","volume":"34","author":"D Kontis","year":"2010","unstructured":"Kontis D, Theochari E, Kleisas S, et al. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1333\u201341.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"4552_CR53","doi-asserted-by":"crossref","unstructured":"Honig A, Arts B, Ponds R, Riedel W. Lithium induced cognitive side-effects in bipolar disorder: a qualitative analysis and implications for daily practice. International clinical psychopharmacology. 1999.","DOI":"10.1097\/00004850-199905002-00003"},{"issue":"3","key":"4552_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00213-003-1592-x","volume":"170","author":"AK Pachet","year":"2003","unstructured":"Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. Psychopharmacology. 2003;170(3):225\u201334.","journal-title":"Psychopharmacology"},{"issue":"1","key":"4552_CR55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1586\/14737175.9.1.55","volume":"9","author":"L Citrome","year":"2009","unstructured":"Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother. 2009;9(1):55\u201371.","journal-title":"Expert Rev Neurother"},{"key":"4552_CR56","doi-asserted-by":"publisher","unstructured":"Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ. Lithium for schizophrenia. Cochrane Database of Systematic Reviews. 2015;(10):CD003834. https:\/\/doi.org\/10.1002\/14651858.CD003834.","DOI":"10.1002\/14651858.CD003834"},{"key":"4552_CR57","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fpsyt.2018.00622","volume":"9","author":"NE MacKenzie","year":"2018","unstructured":"MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018;9:622.","journal-title":"Front Psychiatry"},{"issue":"7","key":"4552_CR58","doi-asserted-by":"publisher","first-page":"e101689","DOI":"10.1371\/journal.pone.0101689","volume":"9","author":"J Veijola","year":"2014","unstructured":"Veijola J, Guo JY, Moilanen JS, et al. Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS ONE. 2014;9(7):e101689.","journal-title":"PLoS ONE"},{"issue":"6","key":"4552_CR59","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","volume":"170","author":"NC Andreasen","year":"2013","unstructured":"Andreasen NC, Liu D, Ziebell S, Vora A, Ho B-C. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170(6):609\u201315.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"4552_CR60","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.neubiorev.2013.06.001","volume":"37","author":"P Fusar-Poli","year":"2013","unstructured":"Fusar-Poli P, Smieskova R, Kempton M, Ho B, Andreasen N, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37(8):1680\u201391.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"4552_CR61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","volume":"166","author":"M Davidson","year":"2009","unstructured":"Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166(6):675\u201382.","journal-title":"Am J Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-023-04552-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T04:08:14Z","timestamp":1674533294000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-023-04552-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4552"],"URL":"https:\/\/doi.org\/10.1186\/s12888-023-04552-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"9 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics and Research Committee at the Psychiatric Hospital of the Cross approved this study (HPC-024\u20132018) in compliance with the Hospital\u2019s Regulatory Research Protocol. The purpose and requirement of the study were explained to each participant. Written informed consent was obtained on the consent form. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}